{
  "abstract": "Introduction: Clinical trials have found semaglutide reduces the risk of major adverse cardiovascular events (MACE) among people with type 2 diabetes (T2D) at high risk of MACE. Less is known about oral semaglutide’s impact on real-world cardiovascular risk.\n\nMethods: This observational cohort study used administrative claims data from Optum’s deidentified Clinformatics® Data Mart Database to compare 3-, modified 3-, 5-, modified 5-, and 2-point MACE, ischemic stroke (IS), myocardial infarction (MI), and all-cause and cardiovascular-related death rates among people with T2D and atherosclerotic cardiovascular disease (ASCVD) who initiated oral semaglutide vs other noninsulin glucose-lowering therapies (ONIGLTs). Cardiovascular outcomes were compared between new users of oral semaglutide and propensity score-matched new users of dipeptidyl peptidase 4 inhibitors (DPP4is) or sodium-glucose cotransporter 2 inhibitors (SGLT2is).\n\nResults: Oral semaglutide users (n = 10,878) had risk reductions of 17% and 21% in 3- and modified 3-point MACE, respectively, and significant risk reductions in 5-, modified 5-, and 2-point MACE, IS, and all-cause death vs ONIGLT users (n = 28,639). People who initiated oral semaglutide (n = 7218) had 22% and 24% lower risks of 3- and modified 3-point MACE, respectively, and significantly lower risks of 5- and modified 5-point MACE, IS, and all-cause death vs people who initiated DPP4is (n = 7218). Compared with SGLT2i users (n = 21,572), oral semaglutide users (n = 7491) had 21% and 22% lower risks of 3- and modified 3-point MACE, respectively, and significantly lower risks of 5-, modified 5-, and 2-point MACE.\n\nConclusion: Consistent with clinical trial evidence, oral semaglutide was associated with a lower risk of cardiovascular outcomes among people with T2D and ASCVD in real-world settings.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s13300-026-01919-8.",
  "abstract_shown": true,
  "affiliations": [
    "Novo Nordisk Inc, Plainsboro, NJ USA",
    "Department of Neurology, Center for Brain and Mind Health, Yale School of Medicine, Yale University, 15 York St, New Haven, CT 06510 USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xi Tan"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuanjie Liang"
    },
    {
      "affs": [
        0
      ],
      "name": "Caichen Zhong"
    },
    {
      "affs": [
        0
      ],
      "name": "Lin Xie"
    },
    {
      "affs": [
        0
      ],
      "name": "Mico Guevarra"
    },
    {
      "affs": [
        0
      ],
      "name": "Caroline Swift"
    },
    {
      "affs": [
        1
      ],
      "name": "Adam de Havenon",
      "orcid": "0000-0001-8178-8597"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2v8ypggp6stw5.bib",
  "cited_by": 0,
  "doi": "10.1007/s13300-026-01919-8",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13728015/",
  "id": "2v8ypggp6stw5",
  "issns": [
    "1869-6953",
    "1869-6961"
  ],
  "landing_url": "https://doi.org/10.1007/s13300-026-01919-8",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2712|Diabetes Treatment and Management"
    ]
  ],
  "openalex": "W7213459286",
  "pdf_url": null,
  "pmcid": "PMC13728015",
  "pmid": "42753116",
  "published": "2026-09-17",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/2v8ypggp6stw5.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:46Z",
      "native_id": "PMC13728015",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s13300-026-01919-8"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Diabetes Treatment and Management",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease",
  "title_text": "Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:21:05Z",
  "url": "https://research.draconitic.com/paper/2v8ypggp6stw5",
  "venue": "Diabetes Therapy",
  "versions": []
}